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Abstract: The Gleason grading system, currently the most powerful prognostic predictor of prostate
cancer, is based solely on the tumor’s histological architecture and has high inter-observer variability.
We propose an automated Gleason scoring system based on deep neural networks for diagnosis of
prostate core needle biopsy samples. To verify its efficacy, the system was trained using 1133 cases of
prostate core needle biopsy samples and validated on 700 cases. Further, system-based diagnosis
results were compared with reference standards derived from three certified pathologists. In addition,
the system’s ability to quantify cancer in terms of tumor length was also evaluated via comparison
with pathologist-based measurements. The results showed a substantial diagnostic concordance
between the system-grade group classification and the reference standard (0.907 quadratic-weighted
Cohen’s kappa coefficient). The system tumor length measurements were also notably closer to the
reference standard (correlation coefficient, R = 0.97) than the original hospital diagnoses (R = 0.90).
We expect this system to assist pathologists to reduce the probability of over- or under-diagnosis
by providing pathologist-level second opinions on the Gleason score when diagnosing prostate
biopsy, and to support research on prostate cancer treatment and prognosis by providing reproducible
diagnosis based on the consistent standards.
Keywords: gleason scoring system; deep neural network; prostate cancer; prostate core needle biopsy
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1. Introduction
Prostate cancer is a leading type of cancer in men worldwide. In 2017, 161,360 new cases of
prostate cancer were reported in the USA, with an estimated 26,730 deaths [1]. Core needle biopsy is
the main method for diagnosis of prostate cancer and recommended to patients whose results from
initial screening tests (e.g., a prostate-specific antigen test, and digital rectal exam) are suspicious of
prostate cancer [2].
The management of prostate cancer differs depending on the patients’ life expectancy,
prostate-specific antigen level, and Gleason score.
The Gleason score is a grading system widely used for evaluating prostate cancer tissues and is the
standard for prognosis prediction and treatment selection. It was first developed by Donald Gleason
and the Veterans’ Administration Cooperative Urologic Research Group between 1966 and 1974. The
Gleason score is based on histologic architecture of tumor and underwent significant revisions in 2005
and 2014 [3–6]. However, as the score is qualitative and subjective, it considerably varies with respect
to inter- and intra-observer variability among pathologists [7,8].
Therefore, a new five-group grading system for prostate cancer was proposed in 2013 at Johns
Hopkins Hospital; specifically, prognostic grade group 1 (Gleason score ≤ 6), prognostic grade
group 2 (Gleason score 3 + 4 = 7), prognostic grade group 3 (Gleason score 4 + 3 = 7), prognostic
grade group 4 (Gleason score 8), and prognostic grade group 5 (Gleason scores 9 and 10) [9]. These
groups were validated in a multi-institutional study, including Johns Hopkins Hospital, the Memorial
Sloan-Kettering Cancer Center, University of Pittsburgh, Cleveland Clinic, and Karolinska Institute
based on patients’ prognosis and biochemical recurrence [10]. Moreover, at the ISUP 2014 consensus
conference, the use of a new prostate cancer grading system in conjunction with the Gleason system
was accepted by a broad consensus (90%) [4].
The development of the whole-slide imaging system, its approval by the Food and Drug
Administration, and studies proving its feasibility for primary diagnosis led to increasing use and
acceptance of digital images for surgical pathology [11]. The digitization of pathological images has
also enabled computational pathology and facilitated research on automated analyses using approaches
such as machine learning.
Among various machine learning techniques, deep learning has recently been gaining attention
for use in various fields. Supported by modern hardware and big data, deep learning utilizes deep
artificial neural networks to automatically learn complex high-level representations, thus avoiding
hand-crafted features. Based on studies on other medical imaging modalities, applications of deep
learning to pathological images have been studied [12,13].
Recently, many studies have been conducted to apply deep learning to whole slide images (WSIs)
diagnosis in several types of cancers, including breast, brain, colon and lung cancer [14–21]. In prostate
cancer, several attempts have been made to detect prostate cancer [22,23] and Gleason scoring [24–26]
using tissue microarrays (TMA), prostatectomy and core needle biopsy samples.
In this paper, we propose an automated Gleason scoring system for prostate core needle biopsy
samples: DeepDx Prostate. To assist pathologists toward more precise and consistent diagnoses,
DeepDx Prostate features a deep neural network architecture trained on more than 1000 annotated
WSIs, along with a viewer and a set of manual annotation tools. We report its performance compared
to the results of a multi-institutional reference standard established by certified pathologists and its
ability to quantify cancer in terms of tumor length compared with pathologist-based measurements.
2. Results
The proposed system performance according to grade groups showed that the system achieved a
higher diagnostic concordance to the reference standard (0.907 in quadratic-weighted kappa) compared
to the original hospital diagnoses (0.870) in the validation dataset. The quadratic-weighted kappa
score between individual pathologists ranged from 0.896 to 0.920 (mean, 0.907), and the mean between
the system score and that of each pathologist was 0.899. The detailed results are listed in Table 1. The
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normalized confusion matrices and representative examples of the analysis through DeepDx Prostate
are shown in Figures 1 and 2, respectively.







Diagnoses Pathologist 1 Pathologist 2 Pathologist 3
DeepDx
Prostate - 0.615/0.907 0.440/0.811 0.550/0.875 0.606/0.906 0.615/0.916
Reference
standard 0.615/0.907 - 0.524/0.870 0.781/0.955 0.809/0.952 0.794/0.943
Original
diagnoses 0.440/0.811 0.524/0.870 - 0.488/0.865 0.494/0.854 0.514/0.852
Pathologist 1 * 0.550/0.875 0.781/0.955 0.488/0.865 - 0.590/0.904 0.574/0.896
Pathologist 2 0.606/0.906 0.809/0.952 0.494/0.854 0.590/0.904 - 0.682/0.920
Pathologist 3 0.615/0.916 0.794/0.943 0.514/0.852 0.574/0.896 0.682/0.920 -
* Genitourinary specialist.
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Figure 1. Normalized confusion matrices between DeepDx Prostate and diagnoses. (A) Binary and 
(B) categorical results against reference standard. (C) Binary and (D) categorical results against 
original hospital diagnoses. 
i r 1. r li f si tri s t r st t a diag oses. ( ) i r
( ) categorical results ag inst referenc stand rd. (C) Binary and (D) categorical results against origi al
hospit l diagnoses.
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Figure 2. Representative examples of core biopsy slides, hematoxylin and eosin (H&E) staining (left), 
and DeepDx Prostate analysis (right) at ×10 magnification. Core needle biopsy of prostate 
corresponding to grade groups (A) 1, (B) 2, (C) 4, and (D) 5. Highlights in yellow, orange, and red 
correspond to regions of Gleason patterns 3, 4, and 5, respectively. 
By excluding cases with ambiguous or empty responses from pathologists, 674 from the 700 
cases were available for difficulty stratification: 147 easy, 505 medium, and 22 hard. Among the easy 
cases, 140 were benign and the system’s analysis showed the highest diagnostic concordance with 
Figure 2. Representative examples of core biopsy slides, hematoxylin and eosin (H&E) staining
(left), and DeepDx Prostate analysis (right) at ×10 magnification. Core needle biopsy of prostate
corresponding to grade groups (A) 1, (B) 2, (C) 4, and (D) 5. Highlights in yellow, orange, and red
correspond to regions of Gleason patterns 3, 4, and 5, respectively.
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By excluding cases with ambiguous or empty responses from pathologists, 674 from the 700 cases
were available for difficulty stratification: 147 easy, 505 medium, and 22 hard. Among the easy cases,
140 were benign and the system’s analysis showed the highest diagnostic concordance with the reference
standards and original hospital diagnoses. In contrast, the hard cases showed the worst correlation, and
the slides with medium difficulty showed moderate correlation. The corresponding kappa coefficient
matrices are detailed in Table 2. Figure 3 shows the distribution within each difficulty level, and
Figure 4 shows the representative images of each level. The concordance between pathologists was
also measured at each difficulty level, as listed in Table 3. Similar to the DeepDx Prostate results, the
correlation between the pathologist-based scores was lower for the hard level than for the easy level.
Table 2. Cohen’s kappa coefficient matrices according to diagnostic difficulty (non-weighted/
quadratic weighted).
Difficulty DeepDx Prostate Reference Standard Original Diagnoses
Easy
DeepDx Prostate - 0.656/0.958 0.634/0.853
Reference standard 0.656/0.958 - 0.611/0.836
Original diagnoses 0.634/0.853 0.611/0.836 -
Medium
DeepDx Prostate - 0.529/0.856 0.311/0.709
Reference standard 0.529/0.856 - 0.423/0.799
Original diagnoses 0.311/0.709 0.423/0.799 -
Hard
DeepDx Prostate - 0.224/0.525 0.255/0.508
Reference standard 0.224/0.525 - 0.224/0.683
Original diagnoses 0.255/0.508 0.224/0.683 -
Table 3. Cohen’s kappa score matrices according to diagnostic difficulty, between pathologists
(non-weighted/quadratic weighted).
Difficulty Pathologist 1 * Pathologist 2 Pathologist 3
Easy
Pathologist 1 * - 0.931/0.990 1.000/1.000
Pathologist 2 0.931/0.990 - 0.931/0.990
Pathologist 3 1.000/1.000 0.931/0.990 -
Medium
Pathologist 1 * - 0.488/0.836 0.463/0.820
Pathologist 2 0.488/0.836 - 0.599/0.863
Pathologist 3 0.463/0.820 0.599/0.863 -
Hard
Pathologist 1 * - 0.273/0.636 0.382/0.815
Pathologist 2 0.273/0.636 - 0.219/0.733
Pathologist 3 0.382/0.815 0.219/0.733 -
* The genitourinary specialist.
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grade group 1. (B) Medium level image showing well-formed individual glands intermingled with 
fused glands. (C) Hard-level image showing high-grade tumor intermingled with intraductal 
carcinoma of the prostate, and (D) very small foci of suspicious tumorous lesion. Highlights in yellow, 
orange, and red correspond to regions of Gleason patterns 3, 4, and 5, respectively. 
The DeepDx Prostate results of tumor length measurements were also notably closer to the 
reference standard than the original hospital diagnoses. Correlation coefficient R between the tumor 
Figure 4. Representative examples of each level of difficulty, H&E staining (left), and DeepDx Prostate
analysis (right) at ×10 magnification. (A) Easy-level image showing well-formed individual glands
in grade group 1. (B) Medium level image showing well-formed individual glands intermingled
with fused glands. (C) Hard-level image showing high-grade tumor intermingled with intraductal
carcinoma of the prostate, and (D) very small foci of suspicious tumorous lesion. Highlights in yellow,
orange, and red correspond to regions of Gleason patterns 3, 4, and 5, respectively.
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The DeepDx Prostate results of tumor length measurements were also notably closer to the
reference standard than the original hospital diagnoses. Correlation coefficient R between the tumor
lengths of the pathologists and DeepDx Prostate was above 0.97, whereas the correlations for the
original diagnoses were all below 0.90, as shown in the correlation matrix of Figure 5.
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3. Discussion
In this study, we introduced an automated Gleason scoring system, trained it using 1133 cases
of prostate core needle biopsy samples, and validated it on 700 cases. The system diagnoses were
compared with the reference standard derived from three certified pathologists. The results sho ed
a substantial diagnostic concordance between the system-grade group classification and reference
standard (non-weighted Cohen’s kappa coefficient was 0.615); this value was higher than that of
the original hospital diagnoses (0.524), or the previously reported agreements between pathologists,
ranging between 0.4 and 0.6 [7,8]. As the Gleason score provi es an i portant index of prognosis
and is one of the key determinants for selecting treatment modalities, the variability between the
diagnoses of different pathologists is of clinical concern. The automated Gleason scoring system can
help pathologists by providing diagnoses based on consistent standards and clear percentages of each
Gleason pattern; this could help urologists in selecti g appropriate treatment modalities.
Several studies have addressed automated Gleason scoring by using deep learning. Arvaniti et al. [24]
reported a deep learning system that achieved comparable results with pathologist evaluatio s on
Gleason scoring with respect to resection specimen of prostate tissue microarray. Likewise, Nagpal et al.
used deep learning based on a modified InceptionV3 classifier to obtain reliable performance in the
grade-group determination on resection specimens from the TCGA dataset [25].
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Both studies focused on patch-level neural networks, whereas our automated Gleason system
implements a pixel-level segmentation neural network, possibly achieving more reliable Cohen’s kappa
coefficient (0.615) and Cohen’s quadratic kappa coefficient (0.907). Similarly, Campanella et al. [22]
trained a patch-level neural network with a massive dataset containing over 10,000 WSIs to access
slide-level prediction and determine whether slides contain cancerous regions through multiple
instance learning. They obtained a high area under the receiver operating characteristic curve (0.98)
without requiring region-level annotations from pathologists.
Moreover, Arvaniti et al. [24] and Nagpal et al. [25] showed the possibility of better risk stratification
in biochemical recurrence or disease progression through deep learning. Nagpal et al. [25] suggested a
fine-grained Gleason scoring system with interpolation methods to enhance biomarkers in prognostic
factors. Our measurements, including grade groups and tumor length obtained from the automated
Gleason scoring system will be studied in survival analysis to test whether these factors are significant
and remain consistent.
We asked three pathologists to assess not only the Gleason score but also the difficulty level
(easy, medium, or hard) of each case. Concordance analysis with respect to difficulty level revealed
that diagnostic concordance was highest in easy cases and deteriorated as case difficulty increased, and
this trend was consistent with the correlation analysis between pathologists. Benign cases composed
the majority of easy cases, whereas notable peaks were observed for grade groups 2 and 5 at both
the medium and hard levels. In grade group 2 (Gleason score 3 + 4), variable judgment about the
composition ratios of Gleason patterns 3 and 4 could be the reason for the lower concordance rate.
While reviewing the hard cases of grade group 5, we found several cases with lesions suspicious of
intraductal carcinoma of the prostate (IDC-P), requiring differential diagnosis from cribriform Gleason
pattern 4 through additional immunohistochemical staining.
We additionally considered cancer quantification in each case. Several methods have been used
in previous studies to evaluate the extent of tumor. Evaluation metrics include the number/fraction
of positive cores, tumor percentage or linear millimeters of carcinoma per core, linear percentage
carcinoma or linear millimeters of carcinoma in core with the greatest tumor volume, and total linear
millimeters of carcinoma across all cores [27,28]. There is no consensus regarding which method is the
best in measuring the extent of tumor in prostate core needle biopsy; several studies have demonstrated
relationships between their respective methods of tumor measurement and certain prognostic factors.
For instance, Quintal et al. [29] found that the percentage of total carcinoma length (in millimeters) in all
cores of a needle biopsy was the strongest predictor for stages beyond pT2 and the risk of biochemical
recurrence following radical prostatectomy. Brimo et al. [30] found that the fraction of positive cores,
the total percentage of carcinoma, and both the total and greatest cancer core length were closely
related to the pathologic stage and biochemical failure.
In this study, we asked pathologists to measure carcinoma in terms of linear millimeters. Tumor
lengths measured by pathologists from WSIs and those automatically determined by the system showed
a high correlation, whereas a notable difference was observed in the measurements obtained from glass
slides of the source hospitals. To determine the tumor area, pathologists usually measure the tumor
length by using a ruler or by manually estimating tumor percentage. However, this is a time-consuming
method, and the results may be inaccurate and vary depending on the pathologists. Despite conflicting
findings about the superiority of measurement methods affecting clinical management, the use of
DeepDx Prostate can provide various tumor quantitative data, such as tumor percentage and length,
and these data can be useful for relating tumor volume to prognosis.
This study had several limitations. As there was no final diagnosis of IDC-P or high-grade
prostatic intraepithelial neoplasia (HGPIN) solely without prostate adenocarcinoma in the validation
set, accurate performance analysis of this lesion could not be performed, although the pathologist
performed gland-level annotation for IDC-P, HGPIN, or ASAP lesions. In addition, we had insufficient
data on precancerous lesions, such as IDC-P, HGPIN, and ASAP. We expected to improve the
system performance to better identify these precancerous lesions by training more data including
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immunohistochemically stained slide images. We also planned to validate the system’s performance
on these lesions by building path-level reference standards and performing path-level analysis.
In addition, we were not able to evaluate the system’s performance on data generated by different
digital image scanners, which have different color tones in practice; in the future, we planned to evaluate
the compatibility by training and evaluating our system using data scanned from different scanners.
Although our system clearly indicates the percentage of each Gleason pattern, validation was not
possible because the pathologists were not asked to describe the percentage of each Gleason pattern,
only tumor length. We also planned to investigate the relationship between grade groups and tumor
volume, including the percentage of Gleason pattern, analyzed through our system with patients’
outcome by using survival data, including the recurrence rate. We would also try to find morphological
phenotypes reflecting poor or better prognosis in a single grade group.
In addition, we would evaluate our system’s performance by comparing only pathologist-based
diagnoses and diagnoses by a pathologist assisted by the proposed system.
4. Materials and Methods
4.1. Data Acquisition and Digitization
A total of 1,833 hematoxylin and eosin (H&E) stained glass slides of prostate needle biopsy
cores along with their original hospital diagnoses were collected from two hospitals: the Korea
University Guro Hospital, Seoul, Korea (Institutional Review Board Approval No. K2017-4488-001)
and the Hanyang University Medical Center, Seoul, Korea (Institutional Review Board Approval
No. 2018-10-010-002). We confirmed that all protocols in this study were performed in accordance with
relevant regulations. The original glass slides from all cores included in the study were randomized and
de-identified, and the institutional review boards of the two hospitals waived the need for informed
consent from each patient. In this paper, we included cases of patients who underwent prostate core
needle biopsy between 2010 and 2018.
After anonymizing patient data, the slides were digitized using Aperio AT2 scanners
(Leica Biosystems Inc., Vista, CA, USA), at ×40 magnification, (i.e., resolution of 0.25 µm/pixel).
After digitization, 700 images were selected for the validation set and balanced according to the grade
groups reported in the original diagnosis. Specifically, we selected 100 acinar adenocarcinoma cases
per grade group and 200 cases including 188 benign and 11 ASAP. However, owing to misdiagnosis
later discovered in the original hospital diagnoses, one benign case was reclassified as grade group 3.
The remaining 1133 cases were used for the discovery set, as detailed in Table 4.
Table 4. Number of slides in the entire dataset for this study.
Category Discovery Validation(Original Hospital Diagnosis)
Validation
(Reference Standards)
Benign 645 188 203
ASAP * 0 11 8
Grade Group 1 145 100 67
Grade Group 2 131 100 111
Grade Group 3 27 101 92
Grade Group 4 122 100 61
Grade Group 5 63 100 158
Total 1133 700 700
* Atypical small acinar proliferation.
4.2. Data Annotation
To develop the deep learning system, an experienced Korea board-certified pathologist provided
gland-level accurate annotations for the 1133 WSIs in the discovery set by using annotation tools of
DeepDx Prostate (Deep Bio Inc., Seoul, Korea). The pathologist blindly reviewed each core, marking
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tissue regions according to one of the following seven classes: benign tissue, acinar adenocarcinoma of
Gleason patterns 3, 4, and 5, HGPIN, intraductal carcinoma of the prostate (IDC-P), and ASAP [4]. WSIs
of high molecular weight cytokeratin (HMW-CK, Mouse monoclonal, Clone 34βE12, 1:200 dilution,
Dako, Glostrup, Denmark) immunohistochemical stain of all cores except benign (according to original
hospital diagnosis) were provided to the pathologist for accurate annotation.
To establish the reference standard diagnoses for the 700 WSIs in the validation set, three
pathologists, who were not involved in the creation of the discovery set, reviewed each WSI
independently for slide-level Gleason scores. The final Gleason scores were defined by majority
vote, and in the case of a disagreement, the diagnoses of the genitourinary specialist were selected.
Along with the Gleason scores, the pathologists were asked to identify each slide for the following
characteristics: the necessity for immunohistochemistry, image quality in terms of slide preparation
and digitization process, diagnostic difficulty of the case based on three levels (easy: cases whose
diagnoses can be made simply by glancing at the WSIs; hard: cases that require consultation or
immunohistochemical staining for diagnosis; medium: others), and tumor length if applicable. All the
measurements, including Gleason scores, tumor lengths, and difficulty levels, were conducted using
annotation tools of DeepDx Prostate.
To prevent any discrepancies that may arise from different color displays, the five pathologists
were provided with identical hardware configurations (iMac Retina 5K display, 27 inches, model 2017;
Apple Inc., Cupertino, CA, USA). Cases diagnosed as another carcinoma, such as urothelial carcinoma,
were excluded from this study.
4.3. Automated Gleason Scoring System
The procedure of the proposed DeepDx Prostate system comprises two steps: patch-level
segmentation and slide-level evaluation. In the first step, the target WSI is split into a grid of 704 × 704
pixel-sized image patches, which are then analyzed by the deep learning system in batches. The deep
learning system retrieves a segmentation result per patch with respect to five categories: non-cancerous;
Gleason patterns 3, 4, and 5; and IDC-P. In the second step, the patch results in a slide are aggregated
into a single heatmap. The proportion of each Gleason pattern within the heatmap determines the final
Gleason score (Figure S3 shows the overall algorithm workflow of our system). The deep learning
system consists of two artificial neural networks of identical structure based on DeepLab v3+ [31]
with additional non-local blocks [32] placed along with the connections between encoder and decoder
of DeepLab v3+, extended from the original to accept image patches of the aforementioned size for
the lesion segmentation. The networks were trained solely on the set of 940,875 image patches and
the same number of corresponding region-level annotations, which was constructed by the patch
extraction on a regular grid of size 352 × 352 from 1133 WSIs in the discovery set, followed by filtering
out the patches with less than 10% being tissues. The networks were trained on eight-GPU machines
using the stochastic gradient descent optimizer with Nesterov momentum. The initial learning rate
was set to 0.01, which was multiplied by 0.1 for each 10 epochs during a total of 120 epochs. During
training, we applied various random image transformations to augment the data. Specifically, image
patches and corresponding annotations were rotated and flipped randomly, and then brightness,
contrast, saturation, and hue were randomly modified to alleviate the effect of color variance from
staining and scanning. In addition, image patches were extracted at sizes in the range of ±20%, and
then resized to 704 pixels × 704 pixels to provide robustness against variation of magnification. The set
of patches was randomly split into five nonoverlapping, equal-sized portions: A, B, C, D, and E. One
network was trained using A, B, C, and D and tuned using E, while the other was trained using B, C, D,
E, and tuned using A. The final system output was defined as the average of the two network outputs.
To further train the deep learning system, given the discovery set of limited size, we adopted
hard-example mining after the initial network training, as in [25]. In the hard-example mining step,
the system-generated patch segmentation results were evaluated using their mean intersection over
union (mIoU) with the pathologist annotations at the beginning of each 15-epoch round. Patches with
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mIoU of less than 0.95 were considered as hard examples and selected for training. The snapshot
and performance of each network on the tuning set were saved at each epoch. After 15 rounds of
hard-example mining, the network snapshots associated with the highest performance were chosen for
each network for the ensemble.
All the data preparation, network training, and evaluation were done with codes implemented in
Python [33], using OpenCV [34] for tissue area detection by Otsu thresholding [35], and PyTorch [36]
for the neural network implementation, training, and data augmentation.
4.4. Evaluation
The results from the validation set were evaluated by considering the grade groups corresponding
to the Gleason scores generated by our system. We compared our system results to the established
reference standard, individual diagnoses of each pathologist, and original diagnoses from the respective
hospitals. The cases reported as ASAP by the original hospital diagnoses were analyzed separately.
The system performance was categorized according to the difficulty levels annotated by the
pathologists, where easy, medium, and hard levels were labeled as 1, 2, and 3, respectively. The
average difficulty level by the pathologists was rounded to the nearest integer to establish the reference
standard of each case.
To assess the system performance based on the grade-group classification, Cohen’s kappa
coefficient was used with and without quadratic weighting. For k number of classes, Cohen’s kappa
coefficient κ is defined as following based on the number of elements in weight wi j, in observed xi j,





j=1 wi jxi j∑k
i=1
∑k
j=1 wi jmi j
, (1)





In addition to classification, we evaluated the system’s ability for quantifying cancer in terms of
tumor length. Tumor length measurements from the original hospital diagnoses, those independently
measured by pathologists using the annotation feature in DeepDx Prostate, and measurements
generated by the system were compared. Pearson correlation coefficient R was used as the evaluation





where X and Y are the compared random variables, σ represents the standard deviation of the
corresponding variable, and COV() is the covariance. Only WSIs found to be Gleason 6 or above in
all criteria (hospital diagnoses, evaluation by reference standard, and system-generated results) were
considered in length comparisons.
5. Conclusions
This paper proposed an automated Gleason scoring system based on deep neural networks for
diagnosis of prostate core needle biopsy samples. The proposed system can assist pathologists to reduce
the probability of over- or under-diagnosis by providing pathologist-level second opinions on the
Gleason score when diagnosing prostate biopsies. We also expect that the proposed system will support
research on prostate cancer treatment and prognosis by providing consistent and reproducible diagnosis.
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